Hepatopulmonary syndrome future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Hepatopulmonary syndrome}} {{CMG}}; {{AE}} {{Soroush}}" |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Hepatopulmonary syndrome}} | {{Hepatopulmonary syndrome}} | ||
{{CMG}}; {{AE}} {{Soroush}} | {{CMG}}; {{AE}} {{Soroush}} | ||
==Overview== | |||
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS. | |||
==Future or Investigational Therapies== | |||
*Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS. | |||
<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref> | |||
<ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref> | |||
<ref name="pmid18668653">Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18668653 Pilot study of pentoxifylline in hepatopulmonary syndrome.] ''Liver Transpl'' 14 (8):1199-203. [http://dx.doi.org/10.1002/lt.21482 DOI:10.1002/lt.21482] PMID: [https://pubmed.gov/18668653 18668653]</ref> | |||
<ref name="pmid12853200">Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12853200 Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome.] ''Lancet'' 362 (9377):43-4. [http://dx.doi.org/10.1016/S0140-6736(03)13807-X DOI:10.1016/S0140-6736(03)13807-X] PMID: [https://pubmed.gov/12853200 12853200]</ref> | |||
<ref name="pmid11074903">Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11074903 Methylene blue improves the hepatopulmonary syndrome.] ''Ann Intern Med'' 133 (9):701-6. [http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00012 DOI:10.7326/0003-4819-133-9-200011070-00012] PMID: [https://pubmed.gov/11074903 11074903]</ref> | |||
<ref name="pmid11497151">Jounieaux V, Leleu O, Mayeux I (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11497151 Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.] ''Intensive Care Med'' 27 (6):1103-4. PMID: [https://pubmed.gov/11497151 11497151]</ref> | |||
==References== | |||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Surgery]] | |||
[[Category:Medicine]] | |||
[[Category:Pulmonology]] | |||
[[Category:Cardiology]] | |||
[[Category:Gastroentrology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 18:05, 6 September 2019
|
Hepatopulmonary syndrome Microchapters |
|
Differentiating Hepatopulmonary syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatopulmonary syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatopulmonary syndrome future or investigational therapies |
|
FDA on Hepatopulmonary syndrome future or investigational therapies |
|
CDC on Hepatopulmonary syndrome future or investigational therapies |
|
Hepatopulmonary syndrome future or investigational therapies in the news |
|
Blogs on Hepatopulmonary syndrome future or investigational therapies |
|
Risk calculators and risk factors for Hepatopulmonary syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS.
Future or Investigational Therapies
- Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS.
References
- ↑ Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol 8 (12):1095-8. DOI:10.1016/j.cgh.2010.08.011 PMID: 20816858
- ↑ Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 168 (16):1820-3. DOI:10.1001/archinte.168.16.1820 PMID: 18779471
- ↑ Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 14 (8):1199-203. DOI:10.1002/lt.21482 PMID: 18668653
- ↑ Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 362 (9377):43-4. DOI:10.1016/S0140-6736(03)13807-X PMID: 12853200
- ↑ Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 (9):701-6. DOI:10.7326/0003-4819-133-9-200011070-00012 PMID: 11074903
- ↑ Jounieaux V, Leleu O, Mayeux I (2001) Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome. Intensive Care Med 27 (6):1103-4. PMID: 11497151